| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine targets lipid membranes and the lipid bilayer structure. Its primary mechanism of action stems from its ability to form lipid bilayers, mimicking biological membranes. As a saturated phosphatidylcholine, it is involved in membrane structure, lipid signaling, and cellular function. Its "target" in research is the study of membrane biophysics and lipid metabolism.
|
|---|---|
| ln Vitro |
In vitro, 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine is used to study lipid bilayer formation and membrane properties. It is a saturated phosphatidylcholine analog that produces a bilayer characterized by high order and reduced fluidity. Its activity is measured by assessing membrane fluidity, bilayer stability, and lipid-protein interactions in model membrane systems.
|
| ln Vivo |
In vivo, 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine is a naturally occurring phospholipid involved in membrane structure and lipid metabolism. As a phosphatidylcholine, it is a component of cell membranes and lipoproteins. It is not a therapeutic agent but is studied in the context of lipid metabolism, membrane biology, and related diseases.
|
| Enzyme Assay |
In vitro enzyme assays with 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine typically involve studying phospholipases, acyltransferases, or other lipid-metabolizing enzymes. The compound is used as a substrate to measure enzyme activity. Standard assays involve incubating the phospholipid with enzyme preparations and measuring the release of fatty acids or lysophospholipid products by chromatographic methods.
|
| Cell Assay |
In vitro cell culture experiments with 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine involve treating various cell types including endothelial cells, macrophages, and epithelial cells. Cells are treated with the phospholipid, and endpoints include assessment of cell proliferation, membrane fluidity, inflammation (cytokine production), and signaling pathway activation. These experiments characterize the biological effects of saturated phosphatidylcholines.
|
| Animal Protocol |
In vivo animal experiments with 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine typically involve administering the compound to animal models of lipid metabolism disorders or inflammation. Key endpoints include assessment of plasma lipid levels, inflammatory markers, and histopathological examination of tissues. These studies investigate the role of saturated phosphatidylcholines in lipid metabolism and disease pathogenesis.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine reflect its role as a lipid. It is present in plasma lipoproteins and cell membranes. As a phospholipid, it is metabolized by phospholipases and acyltransferases. Its levels in plasma and tissues reflect lipid metabolism. It should be stored appropriately for research use.
|
| Toxicity/Toxicokinetics |
1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine has a low toxicity profile as a naturally occurring phospholipid. For research use, standard laboratory safety practices are sufficient. It is not considered a hazardous substance. Comprehensive toxicology studies have not been published for this compound. It is typically handled as a standard laboratory reagent.
|
| Additional Infomation |
1-Myristoyl-2-stearoyl-sn-glycerol-3-phosphocholine is a phosphatidylcholine 32:0, wherein the acyl groups at positions 1 and 2 are myristoyl and stearoyl, respectively. It is a phosphatidylcholine 32:0 and also a tetradecanoic acid ester. Its function is related to octadecanoic acid. PC (14:0/18:0) is a metabolite found or produced in Saccharomyces cerevisiae.
1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine is a saturated phosphatidylcholine analog combining myristoyl (14:0) and stearoyl (18:0) chains. It is a phosphatidylcholine 32:0 that forms a bilayer with high order and reduced fluidity. The compound is used in membrane biophysics and lipid metabolism research. It is not a drug and has no therapeutic indications. |
| Molecular Formula |
C40H80NO8P
|
|---|---|
| Molecular Weight |
734.04
|
| Exact Mass |
733.562
|
| CAS # |
76343-22-1
|
| PubChem CID |
131150
|
| Appearance |
White to off-white solid powder
|
| LogP |
10.88
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
40
|
| Heavy Atom Count |
50
|
| Complexity |
826
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C
|
| InChi Key |
TYAQXZHDAGZOEO-KXQOOQHDSA-N
|
| InChi Code |
InChI=1S/C40H80NO8P/c1-6-8-10-12-14-16-18-19-20-21-23-25-27-29-31-33-40(43)49-38(37-48-50(44,45)47-35-34-41(3,4)5)36-46-39(42)32-30-28-26-24-22-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3/t38-/m1/s1
|
| Chemical Name |
[(2R)-2-octadecanoyloxy-3-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 1.96 mg/mL (2.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3623 mL | 6.8116 mL | 13.6232 mL | |
| 5 mM | 0.2725 mL | 1.3623 mL | 2.7246 mL | |
| 10 mM | 0.1362 mL | 0.6812 mL | 1.3623 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
